largest companion anim veterinari diagnost firm
equip relat consum rapid assay digit radiographi
softwar addit oper refer laboratori
serv veterinari practic well livestock poultri
diagnost segment water diagnost segment compani
found base westbrook main
rich us maintain sell target
report mix result yesterday compani report revenu
million ep inclus tax benefit relat
treatment stock-bas compens non-recur charg relat
implement us tax reform compar expect
million street high includ stock-bas compens tax
benefit view apples-to-appl comparison ep report
charg versu estim estim tax
compani also rais revenu guidanc million ep
guidanc midpoint howev vast major guidanc
increas larg due extern factor underli perform
estim million increas due foreign exchang rate tax
reform account standard chang also million half
result higher growth busi previous model
manag sand-bag somewhat worri
confer call manag state expect organ growth
diagnost recur revenu includ benefit retroact revenu
account standard chang recur revenu made total
revenu conserv estim vet visit growth
continu appear healthi economi continu
gener price realiz would appear us
need knock cover ball achiev guidanc math
pleas see thought section follow discuss even
mediocr year premium instrument placement gener
recur revenu need achiev guidanc appear need
contribut sdma slide snap fecal hit number
manag appear excit sdma slide upcom snap fecal
launch schedul summer think product well
marketplac howev given calcul would appear compani either
conserv guidanc concern veterinari market
fashion whether competit launch troubl trend within
whatev case may think matter time take profit
market share make virtual imposs compani exceed sale
estim sever percentag point also make nearli imposs
compani grow sale faster low- mid-teen rate bar account
chang compani oper leverag avail
see industri support oper margin much
alreadi achiev believ characterist
worth forward ev/sal multipl pe multipl near
maintain sell rate bump price target
increas higher valuat multipl ev/
sale previous believ gener risk factor
valuat methodolog page
disclosur section may found page report
report mix result yesterday compani report revenu million
ep inclus tax benefit relat treatment stock-bas
compens non-recur charg relat implement us tax reform
compar expect million street high includ
stock-bas compens tax benefit view apples-to-appl comparison ep
report charg versu estim estim tax
compar model revenu million million ahead
expect million lpd million million ahead
estim gross margin estim howev
under-perform off-set oper expens came million better
estim
compani rais report revenu guidanc million midpoint
look million driven organ revenu growth compani
preliminari revenu guidanc call million reflect organ
revenu growth increas anticip organ growth rate due million
benefit due chang revenu account standard report revenu also benefit
million foreign exchang rate chang term ep see
report result rang larg function
lower effect tax rate result recent pass tax reform anticip
effect tax rate rang
term individu busi line manag look diagnost recur organ
revenu growth includ benefit chang account standard
growth high-singl digit lpd see flat modest organ growth
compani expect weight averag share fall interest expens
compani see million capit expenditur result expect free cash
flow net incom compar oper cash flow net
clearli strong best street-high revenu estim million
howev rel sale estim out-performance driven everi area asid
us miss estim million judg reaction report
investor pleas report compani guidanc
said headlin number guidanc perceiv favor
would expect mere updat model current exchang rate
million top-lin benefit due chang revenu account standard updat
effect tax rate follow recent pass tax bill result revis estim
almost precis midpoint compani updat guidanc rang revenu
thu see report solid effect updat guidanc factor
extern tax bill chang account standard currenc movement
account nearli increas guidanc except million versu prior
model million half made higher expect growth
busi previous estim
wonder manag take conserv stanc guidanc given uncertainti
around approv launch fecal snap test expect summer abaxi
expect competit launch take sedivu snap
price realiz stellar year premium instrument placement instanc
world-wide growth catalyst placement nearli instrument place sedivu
contribut consum growth quarter along best retent us
chemistri account sinc compani went direct would think reason manag
even bullish cag prospect new year tabl lay
conserv assumpt view sever compon see
project conjectur reason accur would need littl
contribut sdma slide snap fecal order hit number even mediocr
year premium instrument placement get
howev even though think abl achiev guidanc
ev/sal think share price beyond perfect prior month ago
compani sport forward ev/sal basi previou decad sinc
begin compani ad billion worth market cap billion
worth increment sale idexx busi run well present pay
multipl histor lose recip coupl medic devic
diagnost recur recur growth offer manag call growth refer servic contribut account standard per guidancevet visit healthi economi continuescontinu price current trend continuesedivu consum instal contribut growth instrument installedcatalyst placement instal base growth estim in-hous consum avail full yearrefer lab volum exclud vet visit growth price realizationsnap fecal major franchis us sdma custom buy first coupl revenueremain growth idexx laboratori inc
diagnost firm acquisit acquir gener million annual
revenu acquir paid sale awar firm
grow much rapidli capac grow compani
far-and-away market share leader domest world-wide
maintain sell rate rais target increas estim
continu recommend investor take profit current price await favor
base upon idexx result updat guidanc modifi model
estim chang substanti vast major chang due foreign
exchang rate adjust updat effect tax rate due recent pass tax bill
impact chang account standard beyond adjust would
character chang model tweak alter growth rate area
busi point two modifi margin assumpt ten basi point told
look ep revenu million revenu
estimateactualvarianceseg expensessal charge- total oper expense- interest interest incom interests- net incom attribut varianc analysi laboratori inc
figur histor project incom statement
aegi capit corpor compani report
inc haynor cfaestim histor incom year end decemb million except per share total gross gross expensessal gener research impair total oper oper oper ebitda interest incom earn tax non-control net incom attribut share inc
figur histor project annual balanc sheet
aegi capit corpor compani report
inc haynor cfaestim histor balanc year end decemb asset cash market securities- account receiv current total current properti equip long-term asset total current liabilitiesaccount accru defer total current long-term long-term liabil total total stockhold equiti non-control total stockhold equiti inc
